

DEY'S MEDICAL STORES (Manufacturing) LIMITED

Statement of Profit and Loss for the year ended 31st March, 2023

INCOME	Note No.	(RUPEES IN LACS)	
		Year Ended 31.3.2023	Year Ended 31.3.2022
Revenue from operations	16	12186.96	12006.46
Other Income	17	283.69	238.59
TOTAL INCOME		12470.65	13045.05
EXPENDITURE			
Cost of Materials consumed	18	3503.20	3857.92
Purchases of Traded Goods	19	492.75	419.30
Changes in inventories of Finished Goods	20	(38.03)	(497.99)
Work-In-Progress and Traded Goods			
Employee benefits expense	21	4201.12	4019.20
Interest Expenses	22	9.35	8.67
Depreciation	23	123.25	96.14
Other expenses	24	3252.00	2722.09
TOTAL EXPENSES		11623.72	10625.49
Profit before Tax		846.93	2419.56
TAX EXPENSES			
Current Tax		216.67	624.74
Deferred Tax charge/(credit)		(3.70)	(0.25)
Tax adjustments related to earlier years		(0.97)	11.15
Profit/(Loss) for the Year		634.93	1783.92
Earning per equity share of Rs.10/- each fully paid up			
(i) Basic		74.59	209.58
(ii) Diluted		74.59	209.58

Significant Accounting Policies

Notes are an integral part of these financial statements.

In terms of our attached report of even date

For RAY & RAY
Chartered Accountants
(FNN : 301072E)

Asish Kumar Mukhopadhyay
(Asish Kumar Mukhopadhyay)
Partner
Membership No. 056259
Kolkata, the 7th August, 2023



GAUTAM DEY
Managing Director
DIN : 01277238

ANANJIT DEY
Joint Managing Director
DIN : 01277323

DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

		Year Ended 31.3.2023	Year Ended 31.3.2022
Note : 16 REVENUE FROM OPERATIONS			
(a) Sale of Products			
Finished Goods	11168.15	11889.77	
Traded Goods	957.75	868.27	
		12125.90	12759.04
(b) Sale of Services			
Sales Promotion expenses Realised	23.93	16.31	
Handling & Collection Charges	3.99	2.72	
		27.92	19.03
(c) Other Operating Revenue			
Miscellaneous Receipts		33.14	29.39
		12186.96	12805.46
Note : 17 OTHER INCOME			
Interest	240.84	234.23	
Gain on Investment	2.26	-	
Dividend Income	21.16	-	
Insurance Claim	-	1.18	
Liabilities Written Back	18.58	1.36	
Profit on Sale of Property, Plant and Equipment	0.89	1.82	
	283.69	238.59	



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

		(RUPEES IN LACS)	
		Year Ended 31.3.2023	Year Ended 31.3.2022
Note : 18 COST OF MATERIALS CONSUMED			
Opening Stock		480.35	374.26
Add : Purchases		3420.03	3964.01
		<u>3900.38</u>	<u>4338.27</u>
Less : Closing Stock		397.10	480.35
		<u>3503.28</u>	<u>3857.92</u>
Note : 19 PURCHASES OF TRADED GOODS			
Purchases of Traded Goods		<u>492.75</u>	<u>419.38</u>
		492.75	419.38
Note : 20 CHANGE IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND TRADED GOODS			
Closing Stock :			
Finished Goods	2032.04		1993.09
Work-in-Progress	204.65		197.08
Traded Goods	58.71		67.22
	<u>2295.40</u>		<u>2257.37</u>
Less : Opening Stock :			
Finished Goods	1993.09		1517.63
Work-in-Progress	197.06		155.09
Traded Goods	67.22		86.62
Manufactured Intermediaries	-		0.04
	<u>2257.37</u>		<u>1759.38</u>
		<u>(38.03)</u>	<u>(497.99)</u>



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

Year Ended
31.3.2023

Year Ended
31.3.2022

Note : 21 EMPLOYER BENEFITS EXPENSE

Salary, Wages, Bonus and Allowances	3608.63	3475.18
Contribution to Employees' Gratuity Fund	190.00	132.13
Contribution to Employees' Provident Fund	159.98	149.40
Contribution to Employees' Pension Fund	119.13	119.34
One time Settlement	73.66	42.51
Employees' State Insurance	4.10	4.18
Workmen and Staff Welfare Expenses	125.42	96.44

4281.12 4019.28

Note : 22 INTEREST EXPENSES

Interest	9.35	8.57
	9.35	8.57

Note : 23 DEPRECIATION

Depreciation on Property, Plant and Equipment	123.29	96.14
	123.29	96.14



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

Year Ended	Year Ended
31.3.2023	31.3.2022

Note : 24 OTHER EXPENSES :

Power, Light and Fuel	239.48	214.05
Rent	57.52	64.01
Repairs-		
To Buildings	56.69	37.80
To Machineries	88.65	62.65
[Including Rs. 40.61 (2021-22 Rs.55.19)		
for spare parts consumed]		
To others	158.17	115.66
Consumable Stores	37.59	36.68
Security & Manpower supply service charges	131.30	130.04
Hire charges & Other Maintenance	73.26	56.71
Insurance	71.70	65.24
Rates & Taxes	33.04	10.22
Sundry Manufacturing Expenses	29.27	22.39
Travelling, Conveyance & Motor car	779.38	563.19
Publicity & Advertisement	550.95	370.16
Telephone Charges	6.66	6.69
Printing & Stationery	40.68	43.43
Postage & Telegram	11.99	13.86
Bank Charges	2.21	3.34
General Charges	76.55	80.04
Liveries & Draperies	5.88	8.61
Magazines & Journals	1.34	1.49
Entertainment	11.68	4.52
Internal Auditors' Remuneration	15.38	11.92
Freight, Handling & Delivery	325.85	376.77
Subscription	2.11	1.86
Trade Mark Expenses	2.09	0.36
Law Charges	26.80	2.10
Commission to C&F Agent	230.60	224.56
Research & Testing	17.63	16.14
Royalty Paid	13.34	13.44
Commission to Directors	16.88	48.35
Auditors' Remuneration		
Audit Fee	5.00	3.60
Out of Pocket Expenses	-	0.72
In other capacity (for Tax Audit, GST Audit	-	6.83
Miscellaneous Certification)		
Cost Audit Fee	1.13	1.10
Profession tax	0.37	0.25
Breakage	19.62	19.11
Bad Debts Written off	0.23	16.65
Corporate Social Responsibility Activities (Note - 36)	32.09	22.56
Operational Expenditure for C&FA Agent	12.76	11.03
Insurance Claim Rejected	-	0.90
GST Paid	65.94	33.86
	<u>3252.00</u>	<u>2722.09</u>



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

25. Contingent Liabilities and commitments (to the extent not provided for)

A. Contingent Liability :

Counter Guarantee given by the Company to the bank against guarantee given by the bank on account of Purchase of Raw Materials from Foreign Suppliers amounted Rs. Nil against Rs. 59.40 lacs in the previous year.

B. Commitment :

Estimated amount of contracts remaining to be executed on Capital Account and not provided for is Rs. 5.99 Lacs (Previous Year Rs. Nil)

26. A clause in the earlier DPCO stipulated that if the manufacturer purchases the Bulk Drug at a price lower than the price allowed to him by the Government while fixing the price of his formulations, then in such cases the difference to be paid to the Government by the manufacturer. The Government of India had appointed a committee consisting of three members headed by a retired High Court Judge to go into the demands made on the pharmaceutical companies including Dey's Medical Stores (Mfg.) Ltd. under the DPCO. Demands aggregating to Rs. 40549 thousand tentatively had been raised on Dey's Medical Stores (Mfg.) Ltd in 1987, 1990 and 1995 for payment into the Drug Price Equalisation Account (DPEA) under the DPCO 1979 and 1987 read with DPCO 1995, being the difference between the price of bulk drugs according to the Government. The Company disputed the said demands and obtained legal advice that such demands are not sustainable in law.
27. Amount due to Micro Enterprises and Small Enterprises as defined in the Micro, Small and Medium Enterprises Development Act, 2006 as amended amounting to Rs. 54.58 lacs (Previous year Rs. 4.01 lacs). This information has been determined to the extent such parties have been identified on the basis of information available with the Company.

Disclosures as required under Section 22 of The Micro, Small and Medium Enterprises Development Act, 2006, as amended, are as under :

		(Rs. in lacs)	
Sl. No.	Particulars	As at 31.03.2023	As at 31.03.2022
a)	the Principal amount and the interest due thereon remaining unpaid to any supplier on Balance sheet date :	-	-
	Trade Payables : Principal Interest	54.58 NIL	4.01 NIL
b)	the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, as amended, along with the amount of the payment made to the supplier beyond the appointed day during the year:	-	-
c)	the amount of interest due and payable for the year of delay in making payment (which has been paid but beyond appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006:	-	-
d)	the amount of interest accrued and remaining unpaid as on Balance Sheet date:	-	-
e)	the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

28. The Company has proposed Dividend to be distributed to the Equity Shareholders amounting to Rs. 106.40 lacs and the related amount per equity share is (Rs. 12.50 per equity share, subject to approval of shareholders at the ensuing Annual General Meeting.

29. Related Parties :

The details of related parties and transactions entered into with related parties, to the extent identified by the management in accordance with AS-18 on "Related Party Transactions"

(a) Name of Related Parties :

(i) Key Management Personnel :

Mr. Gautam Dey - Managing Director
Mr. Ranajit Dey - Jt. Managing Director

(ii) Holding Company of Dey's Medical Stores (Manufacturing) Limited
Dey's Medical Stores Private Limited

(iii) Enterprises in which key management personnel has significant influence
Dey's Medical (U.P.) Private Limited

(b) Transaction with related parties during the year ended 31st March, 2023 with Outstanding Balance as on 31st March, 2023.

Nature of Transactions	Name of Personnel/ Entity	For the year ended		Outstanding Balance as on	
		31.03.2023	31.03.2022	31.03.2023	31.03.2022
(i) Key Management Personnel :					
Commission Paid/Payable	Mr. Gautam Dey	8.44	24.18	8.44	24.18
Commission Paid/Payable	Mr. Ranajit Dey	8.44	24.18	8.44	24.18
(ii) Enterprises in which KMP has significant influence :					
Inter Company balance	Dey's Medical (U.P.) Private Limited	-	-	4.06	-
Finished goods Purchased	Dey's Medical (U.P.) Private Limited	145.66	99.25	-	-
Handling & Collection received	Dey's Medical (U.P.) Private Limited	3.99	2.72	-	-
Advertising Expenses Recovered	Dey's Medical (U.P.) Private Limited	23.93	16.31	-	-
(iii) Holding Company :					
Inter Company balance	Dey's Medical Stores Private Limited	-	-	(40.06)	36.51
Sales Promotion expenses	Dey's Medical Stores Private Limited	53.45	56.42	-	-
Royalty Paid/Payable	Dey's Medical Stores Private Limited	13.34	13.44	-	-

* Figures in bracket represent Debit Balances.



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

30. The diminution in value of Current Investments is considered by the Management to be of temporary in nature and is due to market fluctuations. In the opinion of the Management, no provision for such temporary diminution in value of Investments is required to be made in the accounts.
31. Actuarial valuation in respect of Gratuity and Leave Encashment has not been done and hence, in view of non availability of such reports, disclosures requirement in terms of Accounting Standard (AS-15) on "Employee Benefits" could not be complied with.
32. Leave Encashment Liability has been provided for during the year on accrual basis as against cash basis followed in earlier years with consequential impact on profit for the year, Shareholders Fund and net assets position as at the year end.
33. Capital Work-in-Progress amounting to Rs. 8.18 lacs (Previous year, NIL) is for a period of less than one year.

34. TRADE PAYABLES AGING SCHEDULE :

(RUPEES IN LACS)

Particulars	Outstanding for following periods from the date of transaction:				Total
	Less than 1 year	1 - 2 Year	2 - 3 Year	More than 3 Year	
Micro enterprises and small enterprise	54.58 (4.01)	-	-	-	54.58 (4.01)
Other than micro enterprises and small enterprises	490.24 (582.67)	0.63 (0.13)	8.24 (0.44)	- (4.90)	499.13 (588.14)
Disputed dues - Micro enterprises and small enterprise	-	-	-	-	-
Other than micro enterprises and small enterprises	-	-	-	-	-
	544.82 (586.68)	0.63 (0.13)	8.24 (0.44)	- (4.90)	553.71 (592.15)

35. TRADE RECEIVABLES AGING SCHEDULE :

(RUPEES IN LACS)

Particulars	Outstanding for following periods from the date of transaction:					Total
	Less than 6 months	6 months 1 year	1 - 2 Year	2 - 3 Year	More than 3 Year	
(i) Undisputed Trade Receivables -						
a) Considered Good	1293.35 (1109.85)	32.39 (9.50)	7.14 (10.91)	5.74 (3.92)	9.17 (20.06)	1347.79 (1154.24)
b) Considered doubtful	-	-	-	-	-	-
(ii) Disputed Trade Receivables -						
a) Considered Good	-	-	-	-	-	-
b) Considered doubtful	-	-	-	-	-	-
	1293.35 (1109.85)	32.39 (9.50)	7.14 (10.91)	5.74 (3.92)	9.17 (20.06)	1347.79 (1154.24)

* Figures in bracket represent figures for the previous year.



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

36. Expenditure on Corporate Social Responsibility (CSR) activities :-

In terms of provisions of Section 135 of the Companies Act, 2013 the required CSR spending for the year is worked out as below:

(RUPEES IN LACS)

Particulars	For the year ended 31.03.2023	For the year ended 31.03.2022
Amount required to be spent by the Company during the year	32.09	22.56
Amount of expenditure incurred	32.09	22.56
Shortfall at the end of the year	Nil	Nil
Nature of CSR activities - Contribution to Prime Minister National Relief Fund	32.09	22.56

27. The Company is exclusively engaged in the business of Pharmaceuticals Products. In the opinion of the Management the above business activities are considered as the only reportable business segment referred to in Accounting Standard (AS 17) on "Segmental Reporting".

38. The particulars of non-resident Shareholders, to whom dividends were remitted during the year in foreign currencies :-

	Current Year	Previous Year
i) Number of non-resident shareholders	1	1
ii) Number of Equity Shares held by them	68	68
iii) Gross amount of dividend (Rs.)	680	136
iv) Years to which dividend relates	2021-22	2020-21

39. Value of Imports on CIF Basis:-

	Current Year (Rs. in lacs.)	Previous Year
Raw Materials	112.03	429.83



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

	31.3.2023	31.3.2022		
	Value	Value		
40. A. PURCHASE OF MATERIALS:				
i) L-Base	365.70	518.40		
ii) Chloramphenicol Palmitate	290.35	403.78		
iii) Others - include materials (None of which individually accounts for more than 10% of total purchase)	2763.98	3041.83		
	3420.03	3964.01		
B. SALES:				
i) Itone Eye Drop	2683.78	2761.58		
ii) Mom Plus Suspension	1425.70	1312.60		
iii) Enteromycetin suspension	1215.98	1335.72		
iv) Others	6800.55	7348.13		
	12125.90	12758.04		
C. CONSUMPTION OF RAW MATERIALS:				
	Value	%	Value	%
a) Raw Materials & Packing Materials:				
Imported (including Duty & Clearing Charges)	112.03	3.20	518.40	13.44
Indigenous	3391.25	96.80	3339.52	86.56
	3503.28	100.00	3857.92	100.00
b) Components & Spare Parts :				
Imported	-	-	-	-
Indigenous	40.61	100.00	55.19	100.00
	40.61	100.00	55.19	100.00
D. WORK-IN-PROGRESS:				
i) Itone Eye Drop	36.53	43.06		
ii) Enteromycetin	62.89	119.34		
iii) Chloramphenicol Powder	31.03	0.16		
iv) Others	74.20	34.50		
	204.65	197.06		



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

41. Additional Regulatory Information :

Ratios :

Particulars	Numerator/Denominator	2022-23	2021-22	Explanation for any changes in the ratio by more than 25% as compared to the preceding year
1. Current Ratio :	Current Asset Current Liabilities	5.95	4.42	-
2. Return on Equity :	Net Profit after Tax Share holders Equity	7 %	20 %	-
3. Inventory Turnover Ratio :	Turnover Average Inventory	5.35	6.38	-
4. Trade Receivable Turnover Ratio:	Net Sales Average Debtors	37.47 Days	35.32 Days	-
5. Trade Payable Turnover Ratio :	Net Purchase Average Creditors	53.45 Days	42.15 Days	-
6. Capital Turnover Ratio :	Net Sales Share holders Equity	1.30	1.46	-
7. Net Profit Turnover Ratio :	Net Profit after Tax Net sales	5.21 %	13.93 %	Due to decrease in turnover and increase in expenses.
8. Return on Capital Employed :	EBIT Total Capital Employed	8.60 %	25.94 %	Due to decrease in turnover and increase in expenses.
9. Return on Investment :	Net Profit Total Assets	5.68 %	16.07 %	Due to decrease in turnover and increase in expenses.

42. Opening Balances have been considered from the previous year's Audited Accounts as audited by other auditors and is relied upon by the Statutory Auditors on the work done by the other auditors.

43. Previous year's figures have been regrouped/rearranged wherever necessary.



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Balance Sheet as at 31st March, 2023

(RUPEES IN LACS)

	Note No.	As at 31.3.2023	As at 31.3.2022
I. EQUITY AND LIABILITIES :			
(1) SHAREHOLDERS' FUNDS :			
(a) Share Capital	2	85.12	85.12
(b) Reserves and Surplus	3	9318.24	8683.31
(2) CURRENT LIABILITIES :			
(a) Trade Payables	4		
(i) Total Outstanding dues of Micro Enterprises and Small Enterprises		54.58	4.01
(ii) Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		499.13	588.14
(b) Other Current Liabilities	5	696.20	727.46
(c) Short-Term Provisions	6	827.52	1018.52
Total :		11180.79	11103.56

II. ASSETS :

(1) NON-CURRENT ASSETS :			
(a) Property, Plant, Equipment and Intangible Assets			
i) Property, Plant and Equipment	7	834.81	726.43
ii) Capital Work-in-Progress (Note - 33)		8.18	-
(b) Deferred Tax Assets (Net)	8	23.64	19.94
(c) Other Non-Current Assets	9	55.85	55.07
(2) CURRENT ASSETS :			
(a) Current Investments	10	352.26	-
(b) Inventories	11	2704.24	2749.13
(c) Trade Receivables	12	1347.79	1154.24
(d) Cash and Cash Equivalents	13	4939.08	4985.28
(e) Short-Term Loans and Advances	14	888.57	1407.42
(f) Other Current Assets	15	26.97	6.05
Total :		11180.79	11103.56

Significant Accounting Policies 1
Notes are an integral part of these financial statements.

In terms of our attached report of even date

For RAY & RAY
Chartered Accountants
(FNN / 301072E)

Asish Kumar Mukhopadhyay
Partner
Membership No. 056359
Kolkata, the 7th August, 2023

GAUTAM DEY
Managing Director
DIN : 01277238

RAHAJIT DEY
Joint Managing Director
DIN : 01277323



Note : 1 SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation of Financial Statements

The financial statements have been prepared as going concern on accrual basis under the historical cost convention and in accordance with the Generally Accepted Accounting Principles (GAAP) in India. These financial statements have been prepared to comply in all material aspects with the accounting standards specified under section 133 of the Companies Act, 2013 (The Act), read with relevant rules issued thereunder.

Use of Estimates

In preparing the financial statements in conformity with accounting principles generally accepted in India, Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities including contingent liabilities as at the date of the financial statements and the amounts of revenue and expenses during the reported period. Actual results could differ from those estimates. Any revision to such estimates is recognized in the period in which the result is known/materialised.

Property, Plant and Equipment

Property, Plant and Equipment are stated at cost (excepting Land and Factory Building which is carried at revalued amount) less accumulated depreciation and net of impairment, if any. Cost includes taxes, duties, freight and other incidental expenses related to acquisition and installation.

Capital Work in Progress

Capital work-in progress comprises expenditure incurred on purchase/construction of assets that are not yet ready for their intended use on the reporting date and carried at cost less impairment, if any.

Depreciation

Depreciation on property, plant and equipment is provided on Written Down Value (WDV) Method based on useful life of the property, plant and equipment as prescribed in Schedule II of Companies Act, 2013 keeping residual value not exceeding 5% in respect of each depreciable items of property, plant and equipment excepting for the factory building, the estimated useful life is still remaining for 21 years with effect from April, 2014, based on an independent technical study and evaluation of the useful life of the asset conducted in this regard and Management's assessment thereof.

Depreciation on additions/disposals of the property, plant and equipment is provided on pro-rata basis with reference to the date of additions/disposals. Any profit/loss arising out of sale/disposal of property, plant and equipment is accounted for and disclosed in the Statement of Profit and Loss.



Impairment of Assets

The carrying value of assets at each Balance Sheet date is reviewed. An impairment loss is recognized whenever the carrying amount of the assets exceeds its recoverable amount.

Investments

- (a) Non-current investments are stated at cost. Provision for diminution is made to recognize the decline other than temporary in the value of the long-term investment.
- (b) Current investments are carried at lower of cost and fair value.

Inventories

Inventories are valued as under:

- i) Raw Materials and Packing Materials at weighted average cost.
- ii) Stores and Spares at cost.
- iii) Work-in-Progress is valued at cost.
- iv) Finished Goods at lower of cost or net realizable value. Cost is determined on First-in First-out (FIFO) Method.
- v) Traded Goods at cost.

Employee Benefits

- (a) Short Term Employee Benefits are recognized in the year in which the service has been rendered by the employee and are measured at cost.
- (b) Provident Fund and Employees State Insurance dues (Defined Contribution Schemes) are administered by Government and contributions to the said funds are charged to Statement of Profit and Loss on accrual basis.
- (c) Leave encashment liability during the year is provided on accrual basis based on Management estimation and not on actuarial valuation as against cash basis followed in earlier years.
- (d) The Company has maintained a Gratuity Fund which is independent of the Company. The Trustees of the Gratuity Fund has taken a "Group Gratuity Policy" with Life Insurance Corporation of India (LIC) for future payment of gratuities to all the retiring employees. The Company is not paying the amount of annual contribution as determined by LIC, instead transferring the gratuity claims amount in respect of retiring employees on an adhoc basis to LIC on a year-to-year basis. The actuarial valuation is not done in respect of gratuity liability.



Revenue Recognition

- (a) Sales are accounted for, on the basis of passing of the ownership in the goods to the customers/owner.
- (b) Sales comprise of sale price of goods excluding trade discount and GST. Service income excludes GST.
- (c) Interest income is recognized on time proportionate basis as per contractual rate of interest.
- (d) Revenue from insurance claims is accounted for as and when the Company's right to receive the same is established.

Foreign Currency Transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of transaction. Foreign currency monetary assets and liabilities are translated at the exchange rate prevailing on the Balance Sheet date. Exchange differences are recognized in the Statement of Profit and Loss.

Research and Development:

Revenue expenditure on Research and Development is charged as expense in the year in which it is incurred. Capital Expenditure, if any, on Research and Development is included in property, plant and equipment and depreciation is provided on the same basis as in respect of property, plant and equipment is provided.

Net Profit or loss for the period, Prior Period Items and Changes in Accounting Policies

Prior Period adjustments and changes in accounting policies having material impact on financial affairs of the Company is separately disclosed in the financial statements.

Taxes on Income

Tax expenses for the period comprising current tax and deferred tax are included in the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the prevailing taxation laws.

Deferred tax resulting from "timing differences" between book and taxable profit is accounted for by using the tax rates and laws that have been enacted/substantially enacted as on the Balance Sheet date. The deferred tax asset is recognized and carried forward only to the extent that there is virtual certainty that the asset will be realized in future.

Provisions, Contingent Liabilities and Contingent Assets

Provision is made based on a reliable estimate when it is probable that an out flow of resources embodying economic benefits will be required to settle obligation.



Dey's Medical Stores (Manufacturing) Limited
Notes to Financial Statements (Contd.)

Contingent liability disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or nonoccurrence of one or more future events not wholly within the control of the company or a present obligation that arises from past event where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

Contingent liabilities, if material, are disclosed by way of notes to the financial statements.

Contingent assets are not recognized or disclosed in the financial statements.



DEV'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

Notes to Financial Statements (Continued)

(RUPEES IN LACS)

	As at 31.3.2023	As at 31.3.2022		
Note : 2. Share Capital				
a) Authorised Share Capital :				
49,50,000 Equity Shares of Rs. 10/- each (2021-22 : 9,50,000 Equity Shares of Rs. 10/- each)	495.00	95.00		
5,000 12% Taxable Cumulative Preference Shares of Rs. 100/- each (2021-22 : 5,000 12% Taxable Cumulative Preference Shares of Rs. 100/- each)	5.00	5.00		
	<u>500.00</u>	<u>100.00</u>		
b) Issued, Subscribed and Paid-up				
8,51,186 Equity Shares of Rs. 10/- each (2021-22 : 8,51,186 Equity Shares of Rs. 10/- each)	85.12	85.12		
	<u>85.12</u>	<u>85.12</u>		
c) The Company is having only one class of Equity Share of Face Value of Rs. 10/- each carrying one vote per share.				
d) 8,36,491 (2021-22: 8,36,491) shares held by its Holding Company, Day's Medical Stores Pvt. Ltd.				
e) Details of Shareholders each holding more than 5% of the aggregate Shares in the Company				
	As at 31.3.2023	As at 31.3.2022		
Name of the Shareholder	Number of Shares	% of holding	Number of Shares	% of holding
Day's Medical Stores Pvt. Ltd. (Holding Company)	8,36,491	98.27	8,36,491	98.27
f) Share held by Promoters at the end of the year			As at 31.3.2023	As at 31.3.2022
Name of the Promoter	Number of Shares	% of holding	Number of Shares	% of holding
Day's Medical Stores Pvt. Ltd. (Holding Company)	8,36,491	98.27	8,36,491	98.27
g) Reconciliation of the Equity Shares outstanding at the beginning and at the end of the reporting period			As at 31.3.2023	As at 31.3.2022
	Number of Shares	Amount Rs. in lacs	Number of Shares	Amount Rs. in lacs
At the beginning of the year	8,51,186	85.12	8,51,186	85.12
Add/Less : During the year	-	-	-	-
At the end of the year	8,51,186	85.12	8,51,186	85.12



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

	As at 31.3.2023	As at 31.3.2022
Note : 3. RESERVES AND SURPLUS		
a) Capital Reserve (Note - 7)		
Acquisition of Building		
As per last Balance Sheet	25.02	27.85
Less : Depreciation on increased	-	2.83
Value of Assets due to Acquisition	25.02	25.02
b) Revaluation Reserve		
Revaluation of Factory, Land and Building		
As per last Balance Sheet	12.70	12.70
c) General Reserve		
As per last Balance Sheet	3481.20	2981.20
Add : Transferred from Surplus	300.00	500.00
	3781.20	3481.20
d) Surplus		
As per last Balance Sheet	5164.39	3965.59
Add : Profit for the year	634.93	1783.92
Less : Appropriations		
Proposed Dividend on Equity Shares	-	85.12
Transferred to General Reserve	300.00	500.00
	5499.32	5164.39
	<u>9218.24</u>	<u>8683.31</u>



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

	(RUPEES IN LACS)	
	As at 31.3.2023	As at 31.3.2022
Note : 4 TRADE PAYABLES (Notes 27 & 34)		
Total Outstanding dues of Micro Enterprises and Small Enterprises	54.58	4.01
Total Outstanding dues of Creditors Other than Micro Enterprises and Small Enterprises	499.13	588.14
	<u>553.71</u>	<u>592.15</u>
Note : 5 OTHER CURRENT LIABILITIES		
Statutory Liabilities	202.83	206.67
Other Liabilities	308.18	338.51
Security Deposits	137.72	127.69
Advance from Customers	46.95	54.12
Unpaid Dividend (Note Below)	0.82	0.47
	<u>696.20</u>	<u>727.46</u>
Note : Unpaid Dividend pertaining to the year 2014-15 amounting to Re. 0.06 lacs is due for transfer to 'Investors' Education and Protection Fund' during the year, but could not be transferred due to some technical problem though the Company has filed Form No. IEPF-1.		
Note : 6 SHORT TERM PROVISIONS		
For Income Tax	521.74	930.40
For Proposed Dividend	-	85.12
For Employee Benefits - Leave Encashment	5.78	-
	<u>527.52</u>	<u>1015.52</u>



Devi's Medical Stores (Manufacturing) Limited

Notes to Financial Statements (Contd.)
NOTE : 7

(RUPEES IN LACS)

PROPERTY, PLANT AND EQUIPMENT

DESCRIPTION	COST/REVALUATION			DEPRECIATION				NET BOOK VALUE		
	As at 1.4.2022	Additions /Adjust- ments	Deductions /Adjust- ments	As at 31.3.2023	Upto 1.4.2022	For the Year	Deductions /Adjust- ments	Upto 31.3.2023	As at 31.3.2023	As at 31.3.2022
Property, Plant and Equipment										
LAND	135.12 *	-	-	135.12	-	-	-	-	135.12	135.12
BUILDING	124.06 **	-	-	124.06	79.31	4.40	-	83.79	40.27	44.75
FACTORY BUILDING	883.28 †	31.07	-	884.35	780.66	5.16	-	785.82	98.63	72.62
PLANT/MACHINERY	1544.52	166.80	-	1701.32	1212.34	71.21	-	1283.55	412.14	326.55
OFFICE EQUIPMENT	12.09	6.02	-	19.11	6.04	0.66	-	9.72	9.39	4.05
ELECTRIC & LABORATORY EQUIPMENT	471.62	22.81	-	494.24	373.30	21.90	-	397.20	97.04	96.33
DATA PROCESSING MACHINE	54.26	6.23	-	60.49	40.74	3.88	-	48.32	13.17	13.52
FURNITURE & FITTINGS	86.88	1.06	-	87.94	84.98	0.46	-	85.44	2.50	1.90
VEHICLES	114.28	7.92	1.89	122.31	84.61	11.78	1.80	94.89	27.64	31.59
TOTAL	3399.12	231.71	1.89	3628.95	2666.98	123.25 (*)	1.80	2788.43	834.81	726.43
Previous Year	3165.12	248.63	14.43	3399.12	2582.07	96.14 (*)	14.08	2666.98	726.43	

Notes :

- (*) Depreciation on Fixed Assets for the year is provided to the extent of depreciable amount on the written down value method in terms of the useful life of assets specified in Schedule II of the Companies Act 2013.
- (**) Flats acquired in Financial Year 2008-07, valued Rs.12.51 lacs are capitalised by crediting Capital Reserve in the Financial Year 2010-11.
- (†) Land & Factory Buildings have been revalued by a Chartered Engineer and Government Registered Valuer on 31.3.1992. The net increase on Revaluation amounting to Rs.646.47 lacs (Land Rs.130.57 lacs and Factory Buildings 713.90 lacs) has been credited to Capital Reserve on 31.3.1992.



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

(RUPEES IN LACS)

As at
31.3.2023

As at
31.3.2022

Note : 8 DEFERRED TAX ASSETS (Net) :

Deferred Tax Assets - Timing Difference in value of depreciable assets	22.18	19.94
Related to Employee Benefits	1.46	-
Deferred Tax Assets (Net)	23.64	19.94

Note : 9 OTHER NON-CURRENT ASSETS (UNSECURED, CONSIDERED GOOD)

Security Deposits	55.95	55.07
	55.95	55.07

Note : 10 CURRENT INVESTMENTS (At lower of cost and fair value)
(Note - 30)

Investment in Mutual Fund (Quoted)		
296369.30 Units (Nil) Fedvrd Balance Advantage Fund-IDCW	50.00	-
521837.78 Units (Nil) HDFC Balance Advantage Fund-IDCW	152.26	-
90707.837 Units (Nil) HDFC Flexi Cap Fund Reg. Plan-IDCW	50.00	-
88147.920 Units (Nil) ICICI Value Discovery Fund-IDCW	25.00	-
93674.390 Units (Nil) ICICI Prudential Bluechip Fund-IDCW	25.00	-
14091.512 Units (Nil) SBI Large and Midcap Fund-IDCW	25.00	-
62661.361 Units (Nil) SBI Contra Fund - Reg. Plan-IDCW	25.00	-
	352.26	-
Aggregate Book Value of Quoted Investments	352.26	-
Aggregate NAV of Investments	346.27	-

Note : 11 INVENTORIES

(As taken, valued and certified by
the Management)

Raw Materials and Packing Materials	397.10	480.35
Work-in-Progress	204.55	197.06
Finished Goods	2032.04	1993.09
Traded Goods	59.71	67.22
	2692.50	2737.72
Stores and Spare Parts	11.74	11.41
	2704.24	2749.13



DEY'S MEDICAL STORES (Manufacturing) LIMITED

Notes to Financial Statements (Contd.)

		(RUPEES IN LACS)	
		As at 31.3.2023	As at 31.3.2022
Note : 12 TRADE RECEIVABLES (UNSECURED, CONSIDERED GOOD) (Note - 35)			
(i) Undisputed Trade Receivables -			
a) Considered Good	1347.79	1154.24	
		1347.79	1154.24
(ii) Disputed Trade Receivables -			
a) Considered Good	-	-	-
b) Considered doubtful	-	-	-
		1347.79	1154.24
Note : 13 CASH AND CASH EQUIVALENTS			
a) Cash and Cash Equivalents			
i) Bank Balance :			
With Scheduled Banks on Current Account	824.88	777.56	
ii) Fixed Deposits with maturity within twelve months	175.00	1040.40	1617.96
iii) Cheques in hand		52.05	33.98
iv) Cash Balance :			
in hand	6.48	7.16	
in transit	37.45	83.01	90.17
		43.93	
b) Other Bank Balance :			
Fixed Deposits with maturity exceeding twelve months		3842.70	2742.85
c) Balance with Banks in Unpaid Dividend Account		0.52	0.47
d) Margin Money for Letter of Credit		-	299.85
		4939.08	4985.28
Note : Fixed Deposits Amounting to Rs. 300 Lacs has been kept as lien with Banks against Letter of Credit facility obtained.			
Note : 14 SHORT TERM LOANS AND ADVANCES (UNSECURED, CONSIDERED GOOD)			
Others -			
For Purchase		14.84	67.37
For Sundries		38.84	38.44
Balance with Govt. Authorities			
For Income-Tax	551.24	800.25	
For Goods and Service Taxes	283.68	501.36	
		834.89	1301.61
		885.57	1407.42
Note : 15 OTHER CURRENT ASSETS (UNSECURED)			
Interest Accrued on Fixed Deposits		26.37	6.05
		26.37	6.05



Dey's Medical Stores (Manufacturing) Limited
Cash Flow Statement for the Year Ended 31st March, 2023.

(Rupees in Lacs)

	Year ended 31.03.2023	Year ended 31.03.2022
A. Cash Flow from Operating Activities :		
Net Profit before tax	845.93	2419.56
Adjustment for :-		
Depreciation	123.25	96.14
Interest Income	(240.84)	(234.23)
Dividend Income	(21.16)	-
Gain on Investment	(2.26)	-
(Profit)/Loss on Sale of Property, Plant & Equipment	(0.85)	(1.82)
Interest Expense	9.35	12.01
	(132.51)	(127.90)
Operating Profit Before Working Capital Changes	714.42	2291.66
Adjustment for :-		
Decrease/(Increase) in Trade & Other Receivables	55.97	225.10
Decrease/(Increase) in Inventories	44.89	(599.75)
(Decrease)/Increase in Trade & Other Payables	(69.70)	(164.51)
	31.16	(539.16)
Cash generated from operation	745.58	1752.50
Income Tax Paid (net of refunds)	(369.75)	(730.17)
Net Cash from Operating Activities (A)	375.83	1022.33
B. Cash Flow from Investing Activities :		
Purchase of Property, Plant and Equipment	(231.71)	(248.63)
Movement in CWIP	(8.18)	-
Proceeds from sale of Property, Plant and Equipment	1.06	2.39
Investment in Mutual Fund	(352.26)	-
Gain on Investment	2.26	-
Movement in Fixed Deposit	65.40	(1340.72)
Dividend Income	21.16	-
Interest Income	240.84	234.23
Net Cash used in Investing Activities (B)	(261.43)	(1352.73)
C. Cash Flow from Financing Activities :		
Non-Current Asset	(0.78)	(431.33)
Interest Expense	(9.35)	(12.01)
Dividend Paid	(85.12)	(17.02)
Net Cash used in Financing Activities (C)	(95.25)	(460.36)
Net increase/(decrease) in Cash & Cash Equivalents (A+B+C)	19.15	(790.76)
Cash & Cash Equivalents at the beginning of the year	901.71	1692.47
Cash & Cash Equivalents at the end of the year	920.86	901.71

Notes : i) The Cash Flow Statement has been prepared under the "Indirect method" as set out in the Accounting Standard 3 : "Cash Flow Statements"
ii) Cash and Cash equivalents represent Cash balance, Cheques in hand and Bank balances in Current Account.

In terms of our attached report of even date

For RAY & RAY
Chartered Accountants
(FVN : 301072E)

Asish Kumar Mukhopadhyay
Partner
Membership No. 056359
Kolkata, the 7th August, 2023



GAURAM DEY
Managing Director
DIN : 01277238

BARAJIT DEY
Joint Managing Director
DIN : 01277323